Hemo Organic Ltd (524590)

Hemo Organic Limited approved the allotment of 34,00,000 equity shares upon the conversion of warrants at Rs 12.50 per share. The company received the remaining 75% consideration amounting to Rs 3.19 crore from two non-promoter entities, Vacro Enterprises and Qmin Realities. This doubles the company's equity base from 34,65,900 shares to 68,65,900 shares, resulting in a ~49.5% dilution. The total inflow of Rs 3.19 crore represents approximately 45% of the company's existing market capitalization of Rs 7 crore.

• 34,00,000 equity shares allotted upon conversion of equal number of warrants at Rs 12.50 per share
• Raised Rs 3,18,75,000 (Rs 3.19 cr) on receipt of 75% balance consideration
• Vacro Enterprises and Qmin Realities each hold a 24.76% post-issue equity stake
• Paid-up equity share capital expanded from 34,65,900 shares to 68,65,900 shares

Hemo Organic Limited's Board has approved the allotment of 34,00,000 equity shares upon conversion of warrants at Rs 12.50 per share to non-promoter entities. The company received the remaining 75% consideration amounting to Rs 3,18,75,000 (Rs 3.19 Cr), bringing total proceeds from this issue to Rs 4.25 Cr. Following this conversion, the total paid-up equity shares expanded from 34,65,900 to 68,65,900, nearly doubling the share capital. The two allottees, Vacro Enterprises and Qmin Realities, now each hold a 24.76% stake in the expanded equity base.

• Allotment of 34,00,000 equity shares upon conversion of warrants at Rs 12.50 per share
• Receipt of remaining 75% warrant exercise consideration aggregating to Rs 3,18,75,000
• Paid-up equity share capital increases from 34,65,900 shares to 68,65,900 shares
• Two non-promoter entities (Vacro Enterprises and Qmin Realities) each acquire a 24.76% stake post-allotment

Hemo Organic Limited has announced the closure of its Register of Members and Share Transfer Books from September 1, 2026 to September 8, 2026, for its 34th Annual General Meeting. The cut-off date to determine shareholders eligible to receive the AGM notice was August 7, 2026. The cut-off date to participate in e-voting has been fixed as September 1, 2026. This is a procedural corporate governance filing with no direct financial impact.

• Book closure period scheduled from September 1, 2026 to September 8, 2026 (both days inclusive)
• Cut-off date for participating in e-voting set as September 1, 2026
• Notice cut-off date for dispatch was August 7, 2026
• Filing pertains to the convening of the 34th Annual General Meeting

Hemo Organic Ltd has released its Annual Report for FY 2025-26 and scheduled its 34th Annual General Meeting (AGM) for September 8, 2026. The company reported a revenue of ‡0.93 crore and a net loss of ‡0.78 crore for the fiscal year. A key agenda item is the appointment of M/s. V S S B & Associates as the new Statutory Auditors for a five-year term, replacing the retiring auditors. The company continues to face financial stress with a reported net worth of ‡0 crore and a high debt-to-equity ratio of 21.08.

• 34th Annual General Meeting scheduled for September 8, 2026, at 3:00 P.M. via video conferencing.
• Record date for determining member voting eligibility is set for September 1, 2026.
• Proposed appointment of M/s. V S S B & Associates as Statutory Auditors for a 5-year term starting from this AGM.
• FY26 annual revenue reported at ‡0.93 crore with an operating margin of -53.76%.
• Promoter holding remains stagnant and low at 16.85% as of the latest June 2026 filing.

Hemo Organic Ltd has issued its Annual Report for FY 2025-26 and scheduled its 34th Annual General Meeting (AGM) for September 8, 2026. The company reported a sharp revenue decline to ₹0.93 Cr in FY26 from ₹2.41 Cr in FY25, alongside a net loss of ₹0.78 Cr. A key agenda item is the appointment of M/s. V S S B & Associates as the new Statutory Auditors for a five-year term, replacing the retiring auditors. The company's financial health remains strained with a net worth of ₹0 Cr and a high debt-to-equity ratio of 21.08.

• 34th Annual General Meeting scheduled for September 8, 2026, via Video Conferencing
• FY26 Revenue reported at ₹0.93 Cr, a 61% decline from ₹2.41 Cr in FY25
• Net loss for FY26 stood at ₹0.78 Cr compared to a profit of ₹0.16 Cr in FY25
• Proposed appointment of M/s. V S S B & Associates as Statutory Auditors for a 5-year term
• Record date for determining voting eligibility set as September 1, 2026

Hemo Organic Ltd has approved the appointment of M/s. V S S B & Associates as its Statutory Auditor for a five-year term, spanning from the 34th AGM to the 39th AGM. This appointment follows the expiration of the tenure of the previous auditor, M/s. M A A K & Associates. The company, which currently has a market capitalization of just Rs 7 Cr and a net worth of Rs 0 Cr, will seek shareholder approval for this change at the Annual General Meeting (AGM) scheduled for September 8, 2026. This is a routine regulatory requirement under the Companies Act, 2013.

• Appointment of M/s. V S S B & Associates for a 5-year consecutive term starting from the 34th AGM.
• Previous auditor M/s. M A A K & Associates' tenure expires at the conclusion of the 34th AGM.
• 34th Annual General Meeting (AGM) scheduled for September 8, 2026, via Video Conferencing.
• Board meeting held on August 13, 2026, concluded at 6:00 P.M. to approve these changes.
• Jitendra Parmar & Associates appointed as Scrutinizer for the e-voting process.

Hemo Organic Ltd has approved the appointment of M/s. V S S B & Associates as its new statutory auditor for a five-year term, starting from the conclusion of the upcoming 34th AGM. The 34th Annual General Meeting is scheduled for September 8, 2026, to be held via video conferencing. This administrative update comes as the company manages a small-scale operation with a TTM revenue of just Rs 1 Cr and a market capitalization of Rs 7 Cr. The board also appointed a scrutinizer for the e-voting process during the AGM.

• Appointment of M/s. V S S B & Associates as Statutory Auditor for a 5-year term until the 39th AGM
• 34th Annual General Meeting (AGM) scheduled for September 8, 2026, at 3:00 P.M.
• Outgoing auditor M/s. M A A K & Associates to conclude tenure at the 34th AGM
• Company maintains a low promoter holding of 16.85% as of June 2026
• Financial context shows a negative net worth of Rs 0 Cr and TTM PAT of Rs -1 Cr

Hemo Organic Ltd has announced the retirement of its statutory auditor, M/s. M A A K & Associates, effective from the conclusion of the 34th Annual General Meeting (AGM) on September 8, 2026. The auditor has completed the maximum permissible tenure under the Companies Act, 2013, and is therefore ineligible for re-appointment. This is a routine regulatory transition for the micro-cap company, which currently has a market capitalization of Rs 7 Cr and a negative net worth. Investors should note the company's fragile financial state, with TTM losses of Rs 1 Cr and a high debt-to-equity ratio of 21.08.

• Statutory Auditor M/s. M A A K & Associates to retire at the conclusion of the 34th AGM on September 8, 2026
• The auditor was originally appointed at the 25th AGM held on September 30, 2017
• The firm completed two terms, with the second term starting from the 30th AGM on September 24, 2022
• Company reports a TTM revenue of Rs 1 Cr against a debt of Rs 3 Cr
• The retirement is mandatory under the provisions of the Companies Act, 2013

Hemo Organic Ltd has appointed M/s. Jitendra Parmar & Associates as Secretarial Auditor for FY 2025-26 and M/s. Umesh Khese & Co. as Internal Auditor for FY 2026-27. These appointments, approved on August 4, 2026, are mandatory compliance steps under the Companies Act, 2013. The company is in a precarious financial state with a net worth of Rs 0 Cr and debt of Rs 3 Cr. With FY26 revenue at just Rs 0.93 Cr, maintaining regulatory compliance is essential for its continued listing despite ongoing losses.

• Secretarial Auditor appointed for FY 2025-26 to ensure legal compliance
• Internal Auditor appointed for FY 2026-27 with over 30 years of professional practice
• Board meeting conducted on August 4, 2026, lasting exactly 1 hour from 5:00 PM to 6:00 PM
• Secretarial Auditor firm brings over 9 years of corporate legal experience

Hemo Organic Ltd has appointed M/s. Jitendra Parmer & Associates as Secretarial Auditor for FY 2025-26 and M/s. Umesh Khese & Co. as Internal Auditor for FY 2026-27. These are mandatory compliance appointments under the Companies Act, 2013. The company is currently in a precarious financial state with a reported net worth of Rs 0 Cr and a debt of Rs 3 Cr as of the latest available data. While these appointments ensure regulatory adherence, they do not address the company's underlying operational challenges, including a net loss of Rs 0.78 Cr in FY26.

• Appointment of M/s. Jitendra Parmer & Associates as Secretarial Auditor for FY 2025-26
• Appointment of M/s. Umesh Khese & Co. as Internal Auditor for FY 2026-27
• Internal Auditor CA Umesh Shyamrao Khese brings over 30 years of professional practice experience
• Secretarial Auditor firm possesses over 9 years of corporate legal and compliance experience
• Company reported a low revenue of Rs 0.93 Cr for the full year FY26